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Monotreme glucagon-like peptide-1 
in venom and gut: one gene – two 
very different functions
Enkhjargal Tsend-Ayush1,*, Chuan He1,*, Mark A. Myers2, Sof Andrikopoulos3, Nicole Wong3, 
Patrick M. Sexton4, Denise Wootten4, Briony E. Forbes1,5,† & Frank Grutzner1,†
The importance of Glucagon like peptide 1 (GLP-1) for metabolic control and insulin release sparked the 
evolution of genes mimicking GLP-1 action in venomous species (e.g. Exendin-4 in Heloderma suspectum 
(gila monster)). We discovered that platypus and echidna express a single GLP-1 peptide in both intestine 
and venom. Specific changes in GLP-1 of monotreme mammals result in resistance to DPP-4 cleavage 
which is also observed in the GLP-1 like Exendin-4 expressed in Heloderma venom. Remarkably we 
discovered that monotremes evolved an alternative mechanism to degrade GLP-1. We also show that 
monotreme GLP-1 stimulates insulin release in cultured rodent islets, but surprisingly shows low receptor 
affinity and bias toward Erk signaling. We propose that these changes in monotreme GLP-1 are the 
result of conflicting function of this peptide in metabolic control and venom. This evolutionary path is 
fundamentally different from the generally accepted idea that conflicting functions in a single gene favour 
duplication and diversification, as is the case for Exendin-4 in gila monster. This provides novel insight into 
the remarkably different metabolic control mechanism and venom function in monotremes and an unique 
example of how different selective pressures act upon a single gene in the absence of gene duplication.
Discovery of the so called incretin effect, where ingested glucose leads to enhanced insulin release compared to 
intravenous glucose administration, revealed the existence of insulin release factors in the gut1. In humans gastric 
inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are the only known insulin stimulating incre-
tin hormones and are released from intestinal cells after food intake2–5. GLP-1 potentiates glucose-stimulated 
insulin secretion from pancreatic beta cells and promotes their survival. GLP-1 acts through the GLP-1 receptor 
(GLP-1R) expressed in the pancreas, brain and other peripheral tissues6. Both GIP and GLP-1 peptides are rapidly 
degraded in the gut and serum by the peptidase dipeptidyl peptidase-4 (DPP-4)7.
During vertebrate evolution the incretin system is highly conserved. Orthologs of the genes encoding the lig-
ands (GCG, GIP), their receptors (GLP-1R, GIPR) and DPP-4 have been identified in a range of vertebrate species 
(reviewed in refs 8–10). Although the GCG is expressed by all vertebrates the role of GLP-1 as an incretin was 
apparently acquired after the divergence of tetrapods from fish11. It is only recently that other functions for GLP-1, 
for example in the brain and cardiovascular system, have also been recognized12,13.
Components of the incretin and insulin systems also play a role in venomous species, which capitalize on the 
rapid and debilitating effects of low blood glucose when targeting prey. Examples of the evolution of venom com-
ponents affecting glucose homeostasis include a Glp-1 like gene exendin-4 expressed in the lizard Heloderma sus-
pectum (Gila monster) venom (now underpinning a type 2 diabetes drug14,15), a fish-like insulin mimetic in cone 
snail venom16 and the GLP-1 degrading enzyme DPP-4 in venom of various snake species17. Acquisition of novel 
gene function, such as the roles of GLP-1 and insulin variants in venom, is generally thought to occur through 
gene duplication followed by functional diversification. The evolutionary origin of exendin genes (exendin 1–4) 
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has not been fully resolved but it seems likely that exendins evolved by duplication from a glucagon-like peptide 
gene precursor14.
We investigated the incretin hormone system in monotremes because of their phylogenetic position as the 
most basal lineage amongst extant mammals. In addition monotremes feature extraordinary changes in their 
digestive system, which has led to loss of genes involved in protein degradation and metabolic control18,19, sug-
gesting unique mechanisms of metabolic homeostasis. Also, monotremes produce venom during breeding season 
and in platypus there is an elaborate venom delivery system, apparently used in competition for mating20,21. These 
observations prompted us to investigate the expression and function of incretin hormones in monotremes. To 
our surprise we discovered that only a single GCG encodes a GLP-1 peptide with two functions, one in venom 
and the other in the gut. Detailed in vitro characterisation of monotreme GLP-1 peptides revealed evolutionary 
signatures that can be explained by selective conflict as a result of the recruitment of this molecule into venom.
Results
Sequence variations in monotreme Gcg genes are present in regions known to be important for 
the regulation of protein function. Gcg, Glp-1r, Gip and Dpp-4 genomic sequences were identified in the 
platypus genome database. At the beginning of this study there were no reported transcript sequences for these 
genes and some of the genomic sequences were incomplete. In this study for the first time cDNA sequences encod-
ing platypus and echidna preproglucagon (encoded by the GCG gene) were identified (Supplementary Table S2). 
Phylogenetic analysis of the preproglucagon amino acid sequence in vertebrates revealed expected tree topology 
but also highlights sequence divergence in the monotreme lineage (Fig. 1b). The proglucagon peptide (Fig. 1a) 
includes a signal peptide (SP), glicentin-related polypeptide (GRPP), glucagon (GCG), intermediate peptides-1 
and -2 (IP-1 and IP-2), glucagon like peptides 1 and 2 (GLP-1 and GLP-2), and is proteolytically processed into 
the mature glucagon-like peptides. While therian mammal GCG genes encode identical GLP-1 protein sequences, 
there are significant changes in the platypus Gcg ortholog. Importantly the inferred sequence of the platypus 
GLP-1 peptide (pGLP-1) differs in 11 of the 30 amino acids (37%) compared to human GLP-1 (hGLP-1, Fig. 1a, 
as reported previously8). A smaller difference was seen between platypus and human GLP-2 (30%) or glucagon 
peptides (20%) (Supplementary Fig. S1). Notably we also discovered specific changes in the DPP-4 cleavage site 
in pGLP-1 (pGLP-1, Ala8 to Ser) (Fig. 1a) and in the platypus GIP peptide (Supplementary Fig. S1, Ala2 to Ser), 
whereas there was no change to the cleavage sites in platypus glucagon or GLP-2 (Supplementary Fig. S1). To 
investigate if this change is also present in the echidna GLP-1 (eGLP-1) we cloned the echidna Gcg (eGcg) tran-
script and found a different amino acid at residue eight (Ala8 to Phe) in the eGLP-1 DPP-4 cleavage site (Fig. 1a), 
as well as a total of 17 differences from hGLP-1 of the 30 amino acids (57% changed). We also saw differences in 
echidna GLP-2 (pGLP-2) from hGLP-2 (45% changed), and in echidna glucagon from human glucagon (17% 
changed) (Supplementary Fig. S2). However, there was no change to the DPP-4 cleavage sites in both peptides. 
Remarkably, GLP-1 peptide sequence comparisons revealed a total of 12 differences between the two monotreme 
sequences (i.e. 40% of the sequence), indicating not only divergence from other mammals but major divergence 
within the monotremes, which separated only 17–48 Million years ago22 (Fig. 1b). These results raise fundamental 
questions about stability and potency of monotreme GLP-1.
Monotreme Gcg and Dpp-4 exhibit similar tissue expression patterns to other mammals, but 
both genes are also expressed in venom. Expression analysis showed that platypus and echidna Gcg, 
Glp-1r and Dpp-4 tissue expression is similar to other mammals (Fig. 2)23,24, suggesting they play a similar role in 
monotremes. Surprisingly, both Gcg and Dpp-4 genes are also expressed in platypus and echidna venom (Fig. 2). 
Figure 1. Identification and characterisation of monotreme Gcg genes and GLP-1 peptides. (a) Alignment 
of human, platypus, echidna and gila monster (Ex-4) GLP-1 sequences highlights hGLP-1 residues involved 
in hGLP-1R binding (underlined)26,27–29. The DPP-4 target site is highlighted in blue. Residues identical to 
those of hGLP-1are boxed (grey). (b) Phylogenetic reconstruction (Neighbor Joining, MEGA4) based on 
preproglucagon amino acid sequences of nine vertebrate species. The preproglucagon peptide domains: signal 
peptide (SP), glicentin-related polypeptide (GRPP), glucagon (GCG), intermediate peptides-1 and -2 (IP-1 and 
IP-2), glucagon like peptides 1 and -2 (GLP-1 and GLP-2).
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In monotremes it is the same Gcg gene encoding GLP-1 that is expressed in gut and venom. This is in contrast to 
Heloderma suspectum, where the Gcg is expressed in gut and Exendin-4 in venom15.
Monotreme GLP-1 peptides are resistant to cleavage by human DPP-4 and human serum 
components but are cleaved in platypus and echidna sera, independently of DPP-4 activity. 
Sequence alignments between human, platypus and echidna GLP-1 proteins (Fig. 1) revealed substitutions at the 
known DPP-4 cleavage site (Ala8 in human) to Ser or Phe in platypus and echidna respectively, predicting that 
DPP-4 cleavage could be affected. To test if the specific amino acid changes at the DPP-4 cleavage site in pGLP-1 
and eGLP-1 result in resistance to degradation, we compared their cleavage to that of human GLP-1 (hGLP-1) 
and the DPP-4 resistant exendin-4 (Ex-4) (Fig. 3). Incubation of the peptides with purified human DPP-4 resulted 
in rapid degradation of hGLP-1 (50% reduction of intact peptide within 1 hour) but not Ex-4. Significantly, both 
echidna and platypus GLP-1 were not degraded by human DPP-4 (Fig. 3a), confirming that monotreme GLP-1 is 
resistant to DPP-4 cleavage. Next we investigated stability in human serum. In albumin-depleted human serum, 
platypus and echidna GLP-1 and Ex-4 remained stable whereas hGLP-1 was rapidly degraded (Fig. 3b). To inves-
tigate if monotremes employ a different way to break down GLP-1, we measured cleavage in platypus and echidna 
serum. Surprisingly, degradation of platypus and echidna GLP-1 was observed when incubated in platypus and 
echidna sera (Fig. 3c,d). Degradation was slower than for hGLP-1 but clearly measurable, with less than 50% 
uncleaved pGLP-1 and eGLP-1 remaining after 11 hours of incubation (Table 1). Interestingly, Ex-4 was cleaved 
slowly in echidna serum but remained intact in platypus and human sera.
DPP-4 is not the only enzyme that can degrade GLP-1. Human neural endopeptidase (NEP24.11), for example 
also cleaves GLP-1 but utilizes different target sites within the peptide25. To further investigate whether mono-
tremes evolved a DPP-4 independent pathway to degrade GLP-1, we firstly confirmed the presence of DPP-4 in 
platypus and echidna sera using a synthetic DPP-4 peptide as a substrate and a DPP-4 inhibitor to prevent this 
cleavage (Supplementary Fig. S3), thus showing that cleavage was due to DPP-4. Despite the presence of DPP-4 
inhibitor we were able to detect cleavage of both monotreme GLP-1 peptides (Supplementary Fig. S4), showing 
that a different enzyme(s) must be responsible for their cleavage in monotreme sera. To gain further insight into 
the mechanism of degradation we used mass spectrometry to analyse the pGLP-1 and eGLP-1 cleavage prod-
ucts. We saw cleavage products that suggested trypsin or chymotrypsin-like activity with cleavage after basic and 
hydrophobic residues (Fig. 4). Together this supports the idea that in monotremes a DPP-4 independent system 
has evolved to regulate GLP-1 half-life and activity.
Monotreme GLP-1 peptides bind with lower affinity to the GLP-1 receptor than human GLP-1. 
We then asked how changes in pGLP-1 and eGLP-1 affect binding and activation of the GLP-1 receptor (GLP-1R). 
All of the known key hGLP-1 residues (underlined in Fig. 1a) involved in binding to the human GLP-1R 
(hGLP-1R) core and four of the six C-terminal residues (excepting Ala25 to Thr and Val33 to Leu) involved in bind-
ing to the hGLP-1R N-terminal domain are conserved in pGLP-126–28. Interestingly, in echidna GLP-1 there is less 
conservation of the receptor binding residues with additional changes at the N-terminal receptor binding Phe12 
(conservatively substituted to Tyr) and Asp15 (changed to Glu) residues. hGLP-1 Gly22, involved in kinking of the 
helix, is a Glu in the extended Ex-4 helix, leading to different modes of interaction with the GLP-1R29. The same 
substitution is seen in the monotreme GLP-1 sequences (Fig. 1a). The platypus GLP-1R amino acid sequence 
(deduced in this study from a sequenced cDNA transcript) is similar to the hGLP-1R (76% identity compared to 
hGLP-1R), including conservation of the residues important for ligand binding (Fig. 5). The pattern of pGLP-1R 
expression (Fig. 2b) is also similar to other mammals30. Receptor binding assays on hGLP-1R overexpressing cells 
showed that, compared to hGLP-1 and Ex-4 both platypus and echidna GLP-1 peptides have lower affinity for the 
Figure 2. Expression of platypus and echidna Gcg, Dpp-4 and Glp-1r in different tissues assessed by RT-
PCR. (a) RT-PCR amplified Gcg, (b) DPP-4 and GLP-1R showing expression in a range of tissues including 
venom gland. Beta actin was used as a positive control. These gel photos have been cropped as indicated.
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human receptor (Fig. 6a, Table 2). hGLP-1 has an almost identical affinity for the platypus GLP-1R (pGLP-1R) 
and the human receptor, but unexpectedly both monotreme GLP-1 peptides had a significantly lower affinity than 
hGLP-1 for the pGLP-1R (Fig. 6b, Table 2). For both receptors monotreme GLP-1 peptides were equipotent with 
the GLP-1R agonist oxyntomodulin (OXM).
Monotreme GLP-1 peptides are less potent in their activation of the GLP-1 receptor. We 
then investigated if this difference in affinities translates into a difference in activation of the GLP-1 receptor. 
As expected monotreme GLP-1 peptides showed significantly less potency than hGLP-1 in assays measuring 
cAMP accumulation, Ca2+ mobilization and ERK1/2 phosphorylation acting through both human and platy-
pus receptors (Fig. 6c–e). eGLP-1 showed a markedly lower potency at both human and platypus receptors that 
was even lower than OXM. Differences in the structure of monotreme GLP-1 peptides compared with hGLP-1 
could account for the lower affinity for the receptor. Circular dichroism spectroscopy (CD) on Ex-4 and hGLP-1 
yielded results similar to previously published data26 and showed that all peptides utilized were folded correctly 
(Supplementary Fig. S5). All peptides retained significant helical content, although pGLP-1 had more and eGLP-1 
had slightly less than hGLP-1. As has been seen with Ex-426, a difference in helical content can result in a different 
mode of interaction with GLP-1R.
Figure 3. Degradation of hGLP-1 (orange circles), pGLP-1 (pink squares), eGLP-1 (green triangles) and Ex-4 
(turquoise inverted triangles) at different incubation times by purified human DPP-4 enzyme (a), human serum 
(b), platypus serum (c) and echidna serum (d) determined by measuring the area under the curve of the intact 
peptide following rHPLC analysis. All values represent means ± S.E.M. (n = 3). ***Statistically significant, 
P < 0.001 peptide remaining at last time point compared with starting peptide concentration.
Peptides
Intact peptide remaining (%)
Human Serum Platypus Serum Echidna Serum
hGLP-1 9.4 ± 2.3 11.4 ± 2.8 10.8 ± 2.7
pGLP-1 96.4 ± 2.0 55.1 ± 3.5* 49.4 ± 2.9*
eGLP-1 99.3 ± 1.8 48.3 ± 3.5* 42.4 ± 4.3*
Ex-4 98.1 ± 1.0 100.5 ± 1.2 70.5 ± 3.1*
Table 1.  Percentage of intact peptides remaining after 11 h incubation in each serum. Data were derived by 
determining the area under the curve following rHPLC analysis. *Statistically significant, P < 0.05 compared 
with human serum group. All values are means ± S.E.M. of three experiments conducted in triplicate.
www.nature.com/scientificreports/
5Scientific RepoRts | 6:37744 | DOI: 10.1038/srep37744
Monotreme GLP-1 elicits a different signalling cascade compared to hGLP-1 when binding to 
the GLP-1 receptor. Closer examination of potencies in receptor activation revealed differential signalling 
bias for monotreme GLP-1 peptides in comparison to that elicited by hGLP-1. Distinct signalling bias arising 
through activation of the GLP-1R by different ligands (including OXM) has recently been established and may, 
at least in part, underlie differences in the physiological profile of naturally occurring ligands of the GLP-1R12. 
Indicators used to determine the signalling profile of peptides include cAMP and intracellular Ca2+ mobilisation, 
which are involved in promotion of insulin release, and pERK1/2 that is part of the mitogenic signalling pathways 
activated via the GLP-1R12. Intriguingly, both the platypus and echidna GLP-1 peptides displayed a distinct pat-
tern of signalling in comparison to hGLP-1 and the clinically approved mimetic Ex-4, which was apparent at both 
the human and platypus GLP-1 receptors (Fig. 6, Supplementary Figs S6 and S7, Table 3). The signalling profile 
of the monotreme GLP-1 peptides closely matched that of OXM with a bias towards pERK1/2, and to a lesser 
extent iCa2+, relative to cAMP (Fig. 6, Supplementary Figs S6 and S7, Table 3), although the bias towards calcium 
mobilisation was less apparent for the pGLP-1 at the human receptors (Fig. 6). These observations suggest that 
monotreme GLP-1 peptides may have gained new as yet undefined functions.
Platypus GLP-1 stimulates insulin release in mouse islet cells. Ultimately, the signal cascade trig-
gered by incretins results in the release of insulin from pancreatic islet cells. We investigated the ability of pGLP-1 
to stimulate insulin release from isolated mouse islets. Results showed that 100 nM pGLP-1 can stimulate insulin 
release in vitro similar to hGLP-1 (Fig. 6f). It appears at least at mouse islet GLP-1R that pGLP-1 would act with 
classical incretin function to promote insulin release, although whether this is the primary function in the platy-
pus remains to be proven.
Discussion
Incretin hormones play a key role in regulation of mammalian metabolism through regulation of insulin secre-
tion as well as by decreasing gastric emptying, food intake, body weight and increasing satiety. The importance 
of insulin regulation and metabolic control has led to recruitment of genes in this pathway in venom function in 
various species. Of medical importance, the discovery of the DPP-4 protease resistant exendin-4 from venom of 
Heloderma suspectum paved the way for the successful development of GLP-1 analogues as important treatments 
for insulin resistant type 2 diabetics.
Monotremes are a fascinating species to investigate this as they represent the third and most basal lineage 
of extant mammals. Importantly they have undergone remarkable changes of their digestive system and feature 
production of potent venom for intraspecific conflict during the breeding season. This prompted us to investigate 
the incretin hormone GLP-1, its receptor (GLP-1R) and the GLP-1 regulatory enzyme DPP-4 in monotremes. 
Overall the key genes in this pathway are conserved in monotremes showing that the insulin release pathway 
Figure 4. Amino acid sequences of cleavage products predicted by MALDI-Mass spectrometry. 
Degradation of hGLP-1, pGLP-1 and eGLP-1 in echidna serum for seven hours was monitored by RP-HPLC, 
fragments were collected and analysed by mass spectometry. Known cleavage sites of DPP-4 and NEP24.11 are 
shown above the hGLP-1 sequence by red and green arrows, respectively. Identified cleavage sites in pGLP-1 
and eGLP-1 are highlighted by blue arrows.
www.nature.com/scientificreports/
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has been maintained despite the extensive changes in the digestive system. However, we discovered remarkable 
changes in GLP-1 sequence and function, which we propose are the result of an unusual evolutionary trajectory 
of this important gene. When we compared platypus and echidna GCG we discovered more changes than would 
be expected given that monotremes diverged only 17–48 Million years ago. This accelerated rate in evolutionary 
change maybe driven by new roles for this gene.
Indeed we discovered that the same monotreme Gcg gene encoding GLP-1 is expressed in monotreme gut and 
venom. In contrast, Ex-4 is only found in the venom of the lizard Heloderma suspectum, with the endogenous 
GLP-1 being DDP-4 sensitive and 84% identical at the amino acids level to human GLP-114,15. Further changes 
involving receptor affinity and activation occurred specifically in monotremes. The GLP-1 peptide found in all 
other mammalian species binds the human GLP-1R with an IC50 of 7.9 × 10−10 M (Table 2), whereas the mono-
treme GLP-1 peptides bind the human and platypus GLP-1R with 50 fold lower affinity. As human GLP-1 is able 
to bind with high affinity and potently activate the platypus GLP-1R (Fig. 6 and (Supplementary Fig. S6), we con-
clude that the platypus receptor functions in a similar manner to hGLP-1R. The significance of the low pGLP-1R 
binding affinity for monotreme GLP-1 peptides to biological activity is as yet unclear.
The phenomenon of ligand-directed signalling bias for GLP-1R has recently been described using the end-
points of cAMP production, pERK1/2 and intracellular Ca2+. For example, hGLP-1 and OXM exhibit bias for 
cAMP over pERK1/2, whereas Ex-4 and GLP-1 [7–37] are not biased. In platypus and echidna the low pGLP-1R 
binding promote a bias towards pERK1/2 signalling compared to human GLP-1. This indicates that the differences 
in monotreme sequences promote a change in the way the peptides interact with the GLP-1R and engendering the 
receptor with a unique conformation to drive distinct receptor function. It also suggests that monotreme GLP-1 
peptides might promote unique, as yet unknown functions through the montreme GLP-1Rs. It will be interesting 
to understand the functional consequences of these changes, which are relevant for possible application in the 
development of GLP-1R agonists for medical application in diabetes treatment and for better understanding of 
the function of these changes in monotreme GLP-1. Lineage specific changes in the sequence and function have 
been described in hystricomorph rodents for the key metabolic gene insulin31. However, monotremes present 
the first example were such a gene, GCG in this case, appears to maintain its role in gut as well as adopting a new 
role in venom. The fact that the venom is used towards members of the same species during the mating season 
may have favored the use of the endogenous gene as the most effective venom component. This may have set the 
scene for an adaptive conflict where on one side selection would favour tolerance to a spike in GLP-1 in blood as 
a result of envenomation and on the other increased potency as a venom component. At the same time insulin 
releasing function of GLP-1 has to be maintained. Insulinotropic effects associated with GLP-1-like peptides 
Figure 5. Schematic diagram of the pGLP-1R highlighting residues equivalent to hGLP-1R important 
for structure and function. Cysteine residues involved in disulphide bonds, denoted by dashed lines, are 
highlighted in yellow. Residues vital for ligand recognition and binding are highlighted in blue12,29,52. Residues 
important for receptor signalling through interaction with Gs-proteins are highlighted in green boxes29. 
Residues different between hGLP-1R and pGLP-1R are highlighted in red. Where a residue is marked blue 
or green but is different to hGLP-1 it is highlighted by a red circle. The putative signal peptide cleavage site is 
depicted with a black arrow.
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have been reported in a range of venomous species including arthropods, reptiles32–36, and recently in cone snail 
venom, which induces severe hypoglycemic shock in its fish prey16. In contrast to the evolution of Gcg-like genes 
and insulin mimetics in other species, monotremes are the first examples of species that have recruited the endog-
enous GLP-1 system into venom. The fact that monotreme GLP-1 is also expressed in monotreme venom raises 
the possibility that DPP-4 resistance is selected for when GLP-1 like molecules are recruited into venom function. 
However, monotremes use venom during intraspecific conflict rather than for envenomation of prey, as is the 
case for most other venomous species. While the DPP-4 resistance is likely a change to enhance the insulino-
tropic effect, the changes in the degradation system may have evolved as a countermeasure to the venom’s effect 
Figure 6. hGLP-1R and pGLP-1R binding and hGLP-1R signalling. Characterisation of the binding of 
hGLP-1 (orange circles), pGLP-1 (pink squares), eGLP-1 (green triangles), Ex-4 (green turquoise inverted 
triangles) and OXM (blue diamonds) in competition with radiolabeled 125I-hGLP-1 (7–36) in FlpInCHO cells 
stably expressing hGLP-1R (a) or pGLP-1R (b). Data are normalized to the maximum 125I-hGLP-1 (7-36) of 
each data set. cAMP accumulation (c), Ca2+ mobilization (d) and ERK1/2 phosphorylation (e) was measured 
using FlpInCHO cells stably expressing hGLP-1R. Data were normalized to the maximal response induced 
by 100 μM forsklin (cAMP), 100 μM ATP (Ca2+) or 10% FBS (ERK1/2) respectively. Data were analysed with 
a three-parameter logistic equation as described previously47. (f ) Glucose-induced insulin release stimulated 
with or without 100 nM each peptide in the presence of either 2.8 mM or 20 mM of glucose. (g) Webs of bias 
generated to quantify and compare signalling bias as described in the methods section. Data are presented on a 
log scale. All values are the means ± S.E.M from at least three independent experiments performed in triplicate. 
*Statistically significant at P < 0.05 versus negative control group without peptide, ***Statistically significant at 
P < 0.001 versus negative control group without peptide.
 Peptides
pIC50
hGLP-1R CHO pGLP-1R CHO
hGLP-1 9.1 ± 0.1 8.9 ± 0.1
pGLP-1 7.9 ± 0.1* 7.4 ± 0.1*,&
eGLP-1 7.6 ± 0.1*,# 7.4 ± 0.1*
Ex-4 9.2 ± 0.1 9.2 ± 0.1
OXM 7.4 ± 0.1* 7.5 ± 0.1*
Table 2.  Characterisation of the binding to human and platypus GLP-1R. Data were analysed with a three-
parameter logistic equation. pIC50 values represents the negative logarithm of the concentration of agonist 
that inhibits binding of half the total concentration of radiolabelled agonist 125I-hGLP-1 (7–36). All values are 
means ± S.E.M. of two or three experiments conducted in triplicate. *Statistically significant, p < 0.05 compared 
with hGLP-1, #Statistically significant, P < 0.05 when comparing eGLP-1 with pGLP-1, &Statistically significant, 
P < 0.05 when compared with binding to hGLP-1R (paired t test).
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mediated by GLP-1 on blood glucose. Further more, it may be that the decreased affinity for the receptor has also 
evolved as a protective mechanism in response to the use of GLP-1 in venom.
Clearly the insulin releasing property of GLP-1 is common in tetrapods but its function in venom is novel 
and monotreme specific. Such acquisition of new function, termed moonlighting, is observed in many genes. 
However, if a newly acquired function results in selective conflict it has been postulated that gene duplication 
is favoured37. Alternatively functional diversification can be the result of duplication events, which maybe the 
case for the many venom genes, including exendins that are likely to be the result of gene duplication involving 
GCG and GIP9,14. In monotremes the changes observed indicate that there is selective conflict between GLP-1’s 
function in venom and its traditional function. It is therefore surprising that GCG gene duplication has not been 
selected for. However, gene duplication would mean an increase in gene dosage, which would likely be deleterious 
as insulin release and glucose tolerance is sensitive to GLP-1 dosage38,39.
In summary, we propose that in monotremes an evolutionary arms race between the function of GLP-1 in 
gut and in venom can explain the changes observed. Evolution of DPP-4 independent GLP-1 degradation and 
decreased receptor activation may have evolved in response to GLP-1 in venom. The independent evolution of 
these components affecting glucose homeostasis and insulin release also highlights the importance of metabolic 
control as a target for venomous species. This maybe the first example of a gene where selective conflict has not 
favoured the evolution of gene duplication.
Methods
Materials. For tissue culture Dulbecco’s modified Eagle’s medium (DMEM), RPMI-1640 medium, hygromy-
cin-B, and Fluo-4 acetoxymethyl ester were used (Invitrogen Carlsbad, CA). AlphaScreen reagents, 125I-Ex(9–39), 
125I-hGLP-1 and 384-well ProxiPlates were purchased from PerkinElmer Life and Analytical Sciences (Waltham, 
MA). hGLP-1, pGLP-1, eGLP-1 and Ex-4 were purchased from GL Biochem (Shanghai) Ltd. (Shanghai, China). 
All other reagents were purchased from Sigma-Aldrich (St. Louis, MO) or BDH Merck (Melbourne, VIC, 
Australia) and were of an analytical grade. The parental INS-1 (832/13) cell line was kindly provided by Chris 
Newgard40.
RNA extraction. Platypus and echidna tissues were obtained from adult animals in accordance with ethics 
guidelines (approved by Adelaide University Animal Ethics Committee permit AEC S-49–200 to F.G). Total RNA 
was extracted from snap frozen platypus tissues (frontal cortex, pancreas, liver, lung, small intestine, stomach, 
heart, venom gland, testis, muscle, lymph and kidney) and echidna tissue (small intestine, pancreas, liver, venom 
gland, heart and brain) using TRIzol (Invitrogen, USA) according to the manufacture’s instructions. RNA was 
resuspended in nuclease free water and stored at −80 °C.
Phylogeny. An evolutionary comparison was made of monotreme GCG genes with orthologues in other ver-
tebrate species (encoded by GCG genes listed in Supplementary Table S2). The phylogenetic tree was constructed 
based on the preproglucagon multiple amino acid sequence alignment using ClustalW241. Neighbor Joining algo-
rithm with bootstrap analysis using 1000 replicates was conducted in MEGA4 software using standard settings42. 
The evolutionary distances were computed using the Poisson correction method and are in the units of the num-
ber of amino acid substitutions per site43. The analysis involved 9 amino acid sequences. All positions containing 
gaps and missing data were eliminated.
cDNA synthesis. cDNA was synthesized from 3 μg RNA with Superscript III Reverse Transcriptase 
(Invitrogen) following the manufacture’s instructions. Briefly, RNAs were treated with DNase I (Roche) to remove 
genomic DNA, incubated with 50 ng of random hexamers and 0.5 μl of 10 mM dNTPs for 5 min at 65 °C. After 
incubation, 2 μl of 5 × First-strand RT buffer, 0.5 μl of 0.1 M dithiothreitol (DTT), 0.5 μl of RNaseOUT™ (40 U/μl), 
and 0.5 μl SuperScript III Reverse Transcriptase (200 U/μl) were added and incubated at 25 °C for 10 min, and then 
50 °C for 50 min, followed by the final termination at 85 °C for 5 min. Finally, 0.2 μl of RNase H (Biolabs, 5 U/μl) 
were added to each tube and incubated at 37 °C for 20 min. cDNAs were stored at −20 °C.
Peptides
pEC50
hGLP-1R CHO pGLP-1R CHO INS-1 (832/13)
cAMP accumulation Ca2+ mobilization pERK1/2 cAMP accumulation Ca2+ mobilization pERK1/2 cAMP accumulation
hGLP-1 10.5 ± 0.1 7.8 ± 0.1 8.8 ± 0.1 10.7 ± 0.1 8.3 ± 0.1& 8.9 ± 0.1 9.6 ± 0.3
pGLP-1 8.7 ± 0.1* 6.5 ± 0.1* 7.9 ± 0.1* 8.8 ± 0.1* 7.0 ± 0.1*,& 8.4 ± 0.1& 7.6 ± 0.3*
eGLP-1 6.9 ± 0.1*,# 5.0 ± 0.2*,# 6.1 ± 0.1*,# 6.8 ± 0.1*,# 5.0 ± 0.2*,# 6.3 ± 0.1*,# 6.1 ± 0.3*,#
Ex-4 11.1 ± 0.1* 8.4 ± 0.1* 9.0 ± 0.1 11.1 ± 0.1 8.1 ± 0.1 9.2 ± 0.1 10.3 ± 0.2
OXM 8.0 ± 0.1* 6.4 ± 0.1* 7.8 ± 0.1* 7.8 ± 0.1* 6.4 ± 0.1* 8.1 ± 0.1* 8.6 ± 0.3
Table 3.  Characterisation of activation of human and platypus GLP-1R. Data were analysed with a three-
parameter logistic equation as defined in refs 46, 47 and 49, where pEC50 values represent the negative logarithm 
of the concentration of agonist that produces half the maximal response. All values are means ± S.E.M. of at least 
three experiments conducted in triplicate. *Statistically significant, p < 0.05 compared with hGLP-1; #Statistically 
significant, p < 0.05 when comparing eGLP-1 with pGLP-1. &Statistically significant, p < 0.05 when compared 
with data on the hGLP-1R (paired t test).
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RT-PCR. RT-PCR was performed to detect the presence of Gcg, Dpp-4 and Glp-1r mRNA in different plat-
ypus and echidna tissues. Gene-specific primers (pGcg, pGLP1R and pDPP-4 sense and anti-sense primers in 
Supplementary Table S1) were designed based on the known coding sequences of pGcg, pGlp-1r or pDpp-4. 
Amplification cycles were: initial denaturation at 94 °C for 3 min, followed by 35 cycles of denaturation at 94 °C 
for 30 s, annealing at 55 °C for 30 s, and extension at 72 °C for 1 min, followed by a final extension at 72 °C for 
7 min. PCR products were run on 1.5% agarose gels and then visualized with ethidium bromide. The identity of 
PCR products were determined by DNA sequencing.
DPP-4 enzyme assays. The enzyme assay was performed in flat-bottom 96- well microplates, 
where each reaction consisted of 100 μL of either 12.5% human, platypus or echidna serum, 0.5 mM of 
H-Ala-Pro-p-nitroanilide (Bachem) as a substrate in the presence/absence of 100 μM of DPP-4 inhibitor P32/98 
(Santa Cruz Biotech) in 100 mM sodium phosphate buffer (PH 7.4) supplemented with 150 mM NaCl and 0.2% 
Tween-20 with a total volume of 200 μM. Reactions were performed at 37 °C. The absorbance of the released p- 
nitroanilide was measured every 2 min over 4 h at 405 nm using a Thermo Scientific Multiskan Ascent microplate 
reader. Enzyme activity was shown as fold changes in absorbance per minute normalized to substrates only group.
DPP-4 cleavage of GLP-1. hGLP-1, pGLP-1, eGLP-1 and Ex-4 (30 μM) were incubated with DPP-4 (3 U/L) 
in sodium phosphate buffer (0.1 M, pH 7.4) for 0, 30, 60, 90 and 120 min in 37 °C incubator, respectively, when 
trifluoroacetic acid (TFA, 0.1%) was added to terminate the reactions. Samples were analysed by RP-HPLC with 
solvent A (0.1% TFA in water) and B (80% acetonitrile in 0.1% aqueous TFA) at a flow rate of 0.5 ml/min. The 
peptides were eluted with a linear gradient of solvent B from 35% to 50% for 30 min. Elution of the peptides was 
detected by measuring UV absorption at 215.8 nm.
Stability of GLP-1 in human, platypus and echidna serum. Human (or platypus or echidna) serum 
was purified by DEAE Affi-Gel Blue Cartridges (Bio-Rad). hGLP-1, pGLP-1, eGLP-1 and Ex-4 (7 μM) were 
incubated with purified human serum in 37 °C incubator in the presence/absence of 100 μM of DPP-4 inhibitor 
P32/98 (Santa Cruz Biotech), and aliquots of the reaction solutions were extracted after 0, 3, 6, 9 and 11 h incuba-
tion respectively, when TFA (0.1%) was added to terminate the reactions. Aliquots were analysed by RP-HPLC. 
Human serum was from the author Briony Forbes and provided with informed consent. We confirm that all 
methods for these studies were carried out in accordance with relevant guidelines and regulations, and all exper-
imental protocols satisfy the Adelaide University Human Research Ethics Committee criteria as being “negligible 
risk research”.
MALDI mass spectrometry. 1 μl of fragments collected from RP-HPLC was sported onto an 800 μm 
Anchor Chip target plate (Bruker Daltonics, Bremen, Germany) separately and air dried. 1 μl of matrix 
[alpha-Cyano-4-hydroxycinnamic acid, 0.5 mg/mL in water/acetonitrile/TFA 10/90/0.1] was spotted subse-
quently and air dried. Mass spectra were acquired on an ultraflex III MALDI-TOF/TOF mass spectrometer 
(Bruker Daltonics) operating in reflective positive mode. Instrument settings were set in flexControl software 
(Version 3.4, Bruker Daltonik GmbH). Sample m/z range was set to 300–4000 Da. 1000 shots were collected for 
the external calibration and sample measurement. External calibration was performed using a 1:20 dilution of 
peptide calibration standard (Bruker Daltonics). Laser intensity and detector gain were manually adjusted for 
optimal resolution. The MS spectra obtained were analysed using the FlexAnalysis software (Version 3.3, Bruker 
Daltonics) employing smoothing, background subtraction and peak detection algorithms.
Circular dichroism spectroscopy (CD). Far-UV CD spectra were measured on a Jasco J-815 spectropolar-
imeter (Jasco Inc., Easton, MD) at 20 °C in a 1 mm quartz cuvette. The scanning range was 185–300 nm at a speed 
of 20 nm/min, the bandwidth was 1 nm, and the spectra were accumulated 5 times. The concentration of hGLP-1, 
pGLP-1, eGLP-1 and Ex-4 was 75 μM in 10 mM sodium phosphate buffer (pH 7.0). The secondary structure of 
each peptide was estimated using the CONTIN algorithm44,45.
Transfections and cell culture. Human and pGLP-1R cDNAs were isogenically integrated into 
FlpIn-Chinese hamster ovary (FlpInCHO) cells (Invitrogen) and selection of receptor-expressing cells 
accomplished by treatment with 600 μg/ml hygromycin B as described previously46. Transfected and parental 
FlpInCHO cells were maintained in DMEM supplemented with 10% heat-inactivated FBS and incubated in a 
humidified environment at 37 °C in 5% CO2. INS-1(832/13) cells were cultured in RPMI-1640 medium supple-
mented with 10 mM HEPES, 10% heat-inactivated FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, 0.05 mM 
β-mercaptoethanol, 100 iU/ml penicillin, and 100 g/ml streptomycin at 37 °C in a humidified 5% CO2 atmosphere.
Radioligand binding assay. FlpInCHO-hGLP-1R and FlpInCHO-pGLP-1R cells were seeded at a density 
of 3 × 104 cells/well and INS-1(832/13) cells at 105 cells/well into 96-well culture plates and incubated overnight at 
37 °C in 5% CO2. Growth media was replaced with binding buffer [phenol-free DMEM containing 25 mM HEPES 
and 0.1% (w/v) BSA] containing 0.7 nM 125I-Ex(9–39) or 0.15 nM 125I-hGLP-1 and increasing concentrations of 
unlabelled ligand. Cells were then incubated overnight at 4 °C, followed by three washes with ice-cold 1 × PBS to 
remove unbound radioligand. Cells were then lysed in 0.1 M NaOH, and radioactivity determined by γ-counting 
as described previously47.
cAMP accumulation assay. FlpInCHO-hGLP-1R and FlpInCHO-pGLP-1R cells were diluted to the den-
sity of 6 × 105 cells/ml and INS-1(832/13) cells to 2 × 106 cells/ml in stimulation buffer [phenol-free DMEM 
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containing 5 mM HEPES, 0.5 mM 3-isobutyl-1-methylxanthine (IBMX) and 0.1% (w/v) BSA], and cAMP 
detection was carried out as described previously48. All values were converted to concentration of cAMP using a 
cAMP standard curve performed in parallel, and data were subsequently normalized to the response of 100 nM 
forskolin.
ERK1/2 phosphorylation assay. FlpInCHO-hGLP-1R and FlpInCHO-pGLP-1R cells were seeded 
at a density of 3 × 104 cells/well into 96-well culture plates and incubated overnight at 37 °C in 5% CO2. 
Receptor-mediated ERK1/2 phosphorylation was determined as previously described47.
Intracellular Ca2+ mobilization assay. FlpInCHO-hGLP-1R and FlpInCHO-pGLP-1R cells were seeded 
at a density of 3 × 104 cells/well into 96-well culture plates and incubated overnight at 37 °C in 5% CO2 and 
receptor-mediated intracellular Ca2+ mobilization determined as described previously49.
Measurement of insulin. Insulin concentrations were determined by a commercially available radioim-
munoassay specific for rodent insulin (Linco Research Immunoassay, St. Charles, MO) as previously described50.
Data analysis. All data were analysed in Prism 6.0c (GraphPad Software Inc., San Diego, CA). Concentration 
response signalling data were analysed using a three-parameter logistic equation as described previously46,47. 
Signalling bias was analysed as described51. Briefly, quantification of signal bias was performed using pharmaco-
logically derived parameters of agonist affinity (Ka) and efficacy (tau) for each ligand in each of the three signal-
ling pathways (cAMP accumulation, ERK1/2 phosphorylation, Intracellular Ca2+ mobilisation). The transduction 
ratio (tau/Ka) was extracted from standard concentration-response data that was analysed with the operational 
model of agonism (Kenakin & Christopoulos 2012). This value was used to calculate ΔΔ(tau/Ka) values through 
normalization of the transduction coefficient (tau/Ka) for each ligand in each signalling pathway to the reference 
ligand (hGLP1 in black) and the reference signalling pathway (cAMP). Data are presented on a log scale.
Statistical analysis was by One-way ANOVA (nonparametric) with Dunnett’s post test unless otherwise stated 
in the figure legends.
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